Skip to content
OpenCapital
Get started

Pacira BioSciences, Inc. PCRX Current ratio

Current ratio at other companies

Avanos Medical logo
Avanos MedicalAVNS
2.5×-0.1×
Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
1.7×+0.6×
AtriCure logo
AtriCureATRC
4.3×+0.2×

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$942.78M-16.0%
Enterprise value$1.21B+1.2%
P/E183.5×—
P/S1.3×-0.3×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%—
Net margin0.7%—
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%—
Debt / equity0.6×+0.2×

Where this comes from

Calculated from Pacira BioSciences, Inc.’s reported figures.

total current assets/total current liabilities=4.7×

Based on the most recent quarter.

The official record: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pacira BioSciences, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pacira BioSciences, Inc.'s current ratio?
Pacira BioSciences, Inc. (PCRX) reported current ratio of 4.7× in Q1 2026.
How has Pacira BioSciences, Inc.'s current ratio changed year-over-year?
Pacira BioSciences, Inc.'s current ratio increased by 96.0% year-over-year, from 2.4× to 4.7×.
What is the long-term trend for Pacira BioSciences, Inc.'s current ratio?
Over 5 years (2020 to 2025), Pacira BioSciences, Inc.'s current ratio has grown at a 12.1% compound annual growth rate (CAGR), from 2.6× to 4.5×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.